Nanotein Technologies

Nanotein Technologies, Inc. is a Berkeley-based biotech startup company that makes next-generation Cell Therapy reagents using their unique platform technology, NanoSpark.

Nanotein has developed and launched a portfolio of soluble, protein-based activation and expansion reagents, including STEM-T for a higher proportion of CD8+ T cells with higher stemness; EVEN-T, a first-in-class reagent to modulate the CD4+:CD8+ T cell ratio; and GROW-NK, a first-in-class feeder-free solution to NK cell activation and expansion.

All products are currently available for purchase as research use only at this time, with GMP products slated to launch toward the end of 2024.